WO2008150954A1

WO2008150954A1 - Treatment of age-related macular degeneration

Info

Publication number: WO2008150954A1
Application number: PCT/US2008/065212
Authority: WO
Inventors: Joseph Weinstock; Sarah Jane Paikowsky
Original assignee: Joseph Weinstock; Sarah Jane Paikowsky
Priority date: 2007-05-31
Filing date: 2008-05-30
Publication date: 2008-12-11
Also published as: EP2170343A1; CA2688439A1; US9072749B2; US20100316731A1

Abstract

Methods and compounds are disclosed for treating dry age-related macular degeneration, and preventing or delaying the onset of wet age-related macular degeneration.

Description

TREATMENT OF AGE-RELATED MACULAR DEGENERATION

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims the benefit of U.S. Provisional Patent Application No. 60/941,106, filed May 31, 2007 and U.S. Provisional Patent Application No. 60/968,195, filed August 27, 2007, the entire disclosures of which are incorporated by reference herein.

BACKGROUND OF THE INVENTION

Age-related macular degeneration (AMD) is the leading cause of legal blindness among people over 65. In industrial countries at least one third of persons over 75 have clinical signs of the disease (21). There are two distinct forms of AMD, known as "wet AMD" and "dry AMD". The characteristics of each are described hereinbelow. The only current treatment for dry AMD is dietary antioxidant and mineral supplements. This delays onset of wet AMD in about 25% of patients and reduces the risk of vision loss in 19% of patients. The present invention provides therapy for dry AMD with the goal of delaying and/or preventing conversion to wet AMD. Age-related macular degeneration most often presents first as the dry form that advances to the wet form in 10-15% of the patients. More serious vision loss is associated with the wet form, but up to 20% of legal blindness is due to the dry form. The dry form of AMD is characterized by macular drusen which are pigmented areas containing dead cells and metabolic products that distort the retina and eventually cause loss of acute vision (4). The wet form is characterized by new blood vessel growth into the retina and subsequent leakage causing catastrophic damage and resulting in severe vision loss. Although there are several current therapies for the more advanced wet form, the only current treatment for dry AMD is daily oral administration of a mixture of antioxidants, vitamins, and metals. This delays progression of dry AMD and slows conversion of dry to wet AMD in about 25% of patients (l, 2, 3).

The retina is a highly metabolizing tissue and requires a high choroidal blood flow to provide oxygen and remove metabolites and dead cells. The necessary blood circulates in the capillaries of the choroid layer of the eye between the retina and sclera and supplies oxygen and nutrients to the reticular pigment epithelium (RPE) and the photoreceptors of the retina. On a weight basis the retina is the most oxygen utilizing tissue in the body with a relative oxygen consumption 50% greater than the brain or kidneys (32). Most of the oxygen is used in the photoreceptors, and thus the RPE and the retina are subjected to the brutal combination of 'toxic oxygen' and UV radiation. One function of the RPE is to each day degrade and dispose of 10% of the outer segments of the photoreceptors. The metabolic products and non-recycled degradation products are removed by transfer to blood in the choroidal capillaries. Drusen, which are the tiny yellow or white accumulations of extracellular material that build up in Bruch's membrane of the eye, are normal with advancing age, and most people over 40 have some hard drusen. However, the presence of larger and more numerous drusen in the macula is a common early sign of AMD and are indicators of increased risk of the complications of AMD. Drusen in the area of the macula interfere with vision by interfering with the light path thus preventing sharp focus on the macular portion of the retina necessary to obtain good visual acuity. An important factor in the formation of drusen is poor blood circulation in the choroid due to constriction and hardening of the capillaries. This allows dead cells and toxic metabolites to accumulate.

The landmark study by the AREDS group found that subjects at high risk for developing advanced stages of AMD reduced this risk by about 25% when treated with a combination of antioxidants (vitamin C, Vitamin E, and beta-carotene/Vitamin A) and minerals (zinc and copper) (3). It also found that the use of this dietary supplement also reduced the risk of central vision loss by 19%. The trial included 3640 participants who had at least early stage AMD. The use of beta-carotene by smokers, or even former smokers, led to an increased risk of cancer. New formulations have been developed in which the beta-carotene has been replaced by a mixture of lutein and zeaxanthin, or lutein alone. These are carotinoids similar to beta-carotene, and are also potent anti-oxidants (28, 29).

SUMMARY OF THE INVENTION

The present invention provides a method and compounds to treat dry AMD, the prevalent form of AMD, and thereby prevent its progression. This objective is achieved in accordance with the present invention by administration of fenoldopam, a fenoldopam prodrug or a pharmaceutically acceptable salt of either of them in monotherapy, or in combination with at least one antioxidcant and/or mineral supplement, for the treatment of dry AMD. The method and compounds of the invention are effective for slowing or preventing the onset of wet AMD in those patients who, because they have many drusen, are predicted to have a high risk of developing wet AMD.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 is a graphical representation of a typical flux rate versus time experiment to evaluate transdermal flux through cadaver human epidermis in ug/cm of fenoldopam mesylate using various permeability enhancers ( — ■ — control; — • — Cla/L-dea, 20/15; —A— Gml/Ml/Pvp, 20/12/16; Laureth -2; — < ♦— ; and Laureth -4, -G-).

FIGURE 2 is a set of graphical representations of the results of time course experiments showing (A) the effect of oral administration of R- fenoldopam (1 and 3 micromoles per kilogram in conscious dogs) on plasma fenoldopam concentration (ng/ml) and (B) renal blood flow (RBF, % change). Baseline RBF = 56 +/- 7 ml/min. Values are mean +/- S. E. (16).

FIGURE 3 is a set of graphical representations of the results of time course experiments showing (A) the effect of oral administration to conscious dogs of SKF R-105058 on plasma fenoldopam concentration; and (B) RBF (16). Baseline renal blood flow = 49 +1-1 ml/min. Values are + S.E.

DETAILED DESCRIPTION OF THE INVENTION

The retina is a highly metabolizing tissue and requires a high choroidal blood flow to provide oxygen and remove metabolites and dead cells. The necessary blood circulates in the capillaries of the choroid layer of the eye between the retina and sclera. In AMD, the choroidal blood flow is lower than normal. The choroid is rich in D 1/5 receptors, and treatment of both animals and humans with dopamine causes an increase in choroidal blood flow (5, 6). In anesthetized rabbits dopamine caused choroidal vasodilation that was blocked by SCH-23390, a Dl/5 antagonist. SKF- 38393, a benzodiazepine similar to fenoldopam (SKF R-82526), and also a Dl/5 agonist, caused a similar vasodilation (6). This showed that the vasodilation is caused by a D1/D5 receptor mediated mechanism. This is analogous to the renal vasodilation seen with SKF 38393 and with fenoldopam (24). This indicates that a suitable DA 1/5 agonist that could be delivered to the choroid without entering the CNS or causing hypotension could be a valuable agent for preventing or inhibiting the progression of macular degeneration.

Fenoldopam SKF 38393 SCH 23390

Fenoldopam (18) and SKF 38393 are well known DAI/5 dopamine receptor agonists while SCH 23390 is a DA 1/5 dopamine receptor antagonist (20). Pharmacologically the major differences between fenoldopam and SKF 38393 are that fenoldopam is more potent and does not cross the blood-brain barrier. Both are racemic, and the activity is carried by the R-enantiomer. Fenoldopam has been investigated extensively as a renal vasodilator and as an antihypertensive, both intravenously and orally. On intravenous dosing, at the lowest active doses the only activity seen is natriuresis (7). As the dose is raised, renal vasodilation occurs, and at higher doses, systemic hypotension develops (8, 9). It has been shown that the DAl receptor density is higher in the proximal cortical tubules responsible for the natriuresis than in the intrarenal arteries (10), thus indicating that receptor density as well as agonist concentration determines the pharmacological expression of receptor stimulation. If the density of DAl receptors in the choroid is sufficiently high, fenoldopam would increase choroidal blood flow without causing significant changes in blood pressure (5).

It has been shown in both animals and humans that dopamine at low doses increases choroidal blood flow by a DAl /5 mechanism. Dopamine may exert its action not only on the choroid capillaries but also on the posterior ciliaries in the cones of fat surrounding the optic nerve and cushioning the eye. Dopamine is not useful in the treatment of AMD because it is short acting and has adrenergic amine effects in addition to its dopaminergic effects. Desirable special properties of a useful dopamine agonist for treatment of dry AMD are: highly selective as a DA 1/5 agonist with no significant D2 activity, no significant other catechol amine activity, does not cross the blood-brain barrier, has no significant effect on heart rate or systemic blood pressure at the doses used to increase choroidal blood flow, and has the ability to increase choroidal blood flow over a useful period of time.

Fenoldopam possesses desirable properties as a dopamine agonist for increasing choroidal blood flow because it is very selective as a DA 1/5 agent, is very potent, and does not cross the blood-brain barrier which would give CNS effects (20). Previous research has demonstrated that it does not have limiting short-term toxicity in animals or humans as demonstrated in oral four- week studies in humans (19).

Fenoldopam's physiological effects are dose related dependent on the site of action. In the kidney at lowest intravenous doses only diuresis is observed. At higher doses renal blood flow is increased. At still higher doses systemic hypotension occurs as other vascular beds become involved. This may be a function of receptor density as well as response of the tissue to dopaminergic stimulation. The choroid has a high density of DA 1/5 receptors that bind dopamine, indicating that the choroidal capillaries might resemble renal capillaries in this manner. Low doses of fenoldopam have been shown to induce renal vasodilation without causing systemic hypotension indicating that similar doses of fenoldopam would similarly increase choroidal blood flow without inducing systemic hypotension. Racemic fenoldopam is currently used as the mesylate (methane sulfonate salt) in intravenous solution (27) as an in hospital hypotensive agent. It exists as two isomers, the R isomer which is responsible for the dopaminergic activity, and the S isomer which has no significant dopaminergic activity. In addition, a synergistic relationship would be expected to exist with the combination of a DA 1/5 agonist that increases choroidal blood flow and an anti- oxidant/mineral supplement. The ingredients of the antioxidant supplement taken orally are carried to the retina by the choroidal blood flow. In AMD the choroidal blood flow is below normal and therefore higher blood levels and/or longer exposure times are needed than if the blood flow was normal. In parts of the retina near areas of low blood flow the ingredients of the supplement may never reach the concentration necessary for a therapeutic effect. Co-administration of fenoldopam and the anti-oxidant/mineral supplement would enhance delivery of the supplement to all parts of the retina including those areas which have only a few functioning choroidal capillaries.

Access to the choroid other than via the blood is difficult. The eye is composed of three major anatomic compartments, the anterior chamber, posterior chamber, and vitreous cavity, that have limited physiological interaction with each other. The retina is located in back of the vitreous cavity, and is protected from the outside by the sclera which is the white, tough, impermeable wall of the eye. Thus most drugs cannot be delivered to the choroid by eyedrops or a depot immediately outside the eye. However, some drugs have been delivered to the retina (and thus to the choroid) by injection into the vitreous chamber of the eye (11), mostly in a delayed release media. Also, some drugs have been delivered to the retina (and thus to the choroid) by trans scleral transport (eye drops) (22, 23) and this would be a convenient and effective dosage route. In some cases the drug has been converted to a prodrug to facilitate this transport. Choroidal blood flow is the usual method of carrying substances to the choroid. An orally absorbed drug can be administered in capsule or tablet form designed for either immediate or sustained release. A sustained release prodrug form would prolong exposure time for a short acting drug.

A conventional dosage form is a low dose fenoldopam tablet with either rapid or slow release properties. It is important to maintain a low blood level of fenoldopam because many of the patients receiving it are elderly and on various other drugs, and adding a potent antihypertensive agent would be a potential complication that would preferably be avoided. As used herein, the term "patient" refers to animals, including mammals, preferably humans.

Fenoldopam is presently marketed only as a solution for intravenous injection which must be diluted before use (27). However, fenoldopam has been studied as an oral formulation at hypotensive doses for periods of up to four weeks (19).

Fenoldopam is a catechol amine, and as such has a short duration of action. The duration of action may be prolonged by the use of a sustained release preparation. The feasibility of such a dose formulation was suggested by a pharmacokinetic study and by the preparation of slow-releasing fenoldopam formulations (12, 26). The balanced drug release and clearance would prevent an excessively high peak blood concentration as is typical with standard formulations when long duration of action is desired. Another drug delivery option would be transdermal transport by means of a patch. This also has the advantage of avoiding peak effects which can occur on oral dosing. Several such systems specifically for fenoldopam have been patented. Such patches are currently successfully used to deliver drugs such as steroids, scopolamine for motion sickness, nitroglycerine for angina, and fentanyl for intractable pain. Three patents have issued which relate to patches that release fenoldopam at a constant rate for up to 96 hours (13, 14, 15).

Figure 1 shows the rate at which fenoldopam is transferred from a transdermal patch, including various permeation enhancers, through human cadaver skin. The enhancers identified in Figure 1 are caproyl lactic acid and luramide diethanolamine, used in a ratio of 20/15 ( — • — ); glycerol monolaurate/myristyl lactate/polyvinyl pyrrolidone, used in a ratio of 20/12/16 ( — ▲ — ); polyethylene glycol (PEG)-2 laurylether (—♦—); and PEG-4 laurylether (—3—).

A third option would be use of a prodrug. SK&F 105058, a triprotected compound, may be suitable for use as a prodrug for fenoldopam. It was shown to release fenoldopam slowly after oral absorption. Fenoldopam blood level and renal vasodilator effect was studied in the dog as a function of time after oral dosing of several prodrugs. SK&F 105058 was the most successful (16,17). However other prodrugs such as esters, carbonates, and carbamates on the benzazepine nitrogen could be used, if desired.

N-¹J-O

The last mentioned prodrugs would have the partial structure , R= lower alkyl, o

^N- U— OCH₂CH₃ a representative example being . If the prodrug is too lipophilic it may cross the blood-brain barrier, so a balance must be achieved. The prodrug could be designed to enhance absorption, or it could be designed to slowly release the active parent after absorption.

Plasma fenoldopam levels and per cent increase of renal blood flow (RBF) on oral dosing in dogs are shown in Figures 2a and 2b. Fenoldopam on oral dosing rapidly gives high drug blood level and concomitant increase in renal blood flow, but both are of relatively short duration. In contrast, the prodrug SKF 10508 gives a more gradual increase of drug blood level, but the increase in renal blood flow is rapid and sustained for a much longer time (greater than 6 hours), as shown in Figures 3A and 3B. It should be noted that in the case of administration of the racemic form of fenoldopam or its prodrugs, e.g., SK&F 105058, twice the dose shown in Figures 2 and 3 would be required to obtain the renal blood flow increases produced by the R- enantiomers (16).

The use of a trans scleral dosage route would require a lipophilic drug form that promotes absorption to the posterior ciliaries imbedded in the cones of fat. However, fenoldopam itself is not lipophilic so a suitable prodrug approach for this would be to mask the aromatic 7,8,4'-hydroxyl groups of fenoldopam as esters of aromatic and aliphatic acids such as benzoic acid and isobutyric acid. These would be rapidly cleaved after absorption.

The oral dose required to obtain the desired therapeutic effect, i.e., treatment or prevention of AMD, should be sufficient to provide a sustained drug plasma level for many hours, but not necessarily for 24 hours per day. An analogy would be the widespread use of short acting diuretics such as furosemide. Useful drug plasma levels of R-fenoldopam are 0.25 to 10 ng/ml, a preferred drug plasma level of 0.25 to 5 ng/ml, and a most preferred level of 0.25 to 2.5 ng/ml. If racemic fenoldopam is used, the drug levels would be twice of those stated above. SK&F 105058, the triprotected compound, may be suitable for use as a prodrug for fenoldopam.

A consequence of increasing choroidal blood flow is not only to increase delivery of oxygen and nutrients to the retina, but also to increase the delivery of systemically dosed pharmaceuticals used to treat eye diseases whose site of action is in the retina, choroid or posterior chamber of the eye. This is especially relevant to AMD where one factor in the disease is reduced choroidal blood flow. The combined use of fenoldopam and systemically or topically dosed drugs for the treatment of wet and dry AMD and glaucoma should enhance delivery of these drugs to their site of action. Useful delivery forms for this use include eye drops and eye ointments.

The landmark study by the AREDS group found that subjects at high risk for developing advanced stages of AMD reduced this risk by about 25% when treated with a combination of antioxidants (vitamin C, Vitamin E, and beta-carotene) and minerals (zinc and copper). They also found that the use of this dietary supplement also reduces the risk of central vision loss by 19%. The trial included 3640 participants who had at least early stage AMD. Daily doses of antioxidants and zinc of the original AREDS supplements were 500 milligrams of vitamin C; 400 international units of vitamin E; 15 milligrams of beta-carotene; 80 milligrams of zinc as zinc oxide; and two milligrams of copper as cupric oxide. The purpose of the copper oxide is to counteract the tendency of zinc to inhibit copper absorption. Beta carotene, a carotinoid, is an important part of the supplement because it is a potent antioxidant. It has been demonstrated to quench singlet oxygen ( O₂), scavenge peroxyl radicals and inhibit lipid peroxidation. However, it was found that smokers, and even former smokers, who took high doses of beta carotene had an increased risk of cancer. With this in mind, formulations of the mixture in which beta carotene was replaced by lutein, or a mixture of lutein and zeaxanthin were developed and are currently marketed for treatment of AMD (29, 30).

Beta-carotene, lutein, zeaxanthin, and meso-zeaxanthin are members of the carotenoid family (29, 30, 31). They are natural fat-soluble yellowish pigments found in some plants, algae and photosynthetic bacteria. They serve as accessory light- gathering pigments and to protect these organisms against the toxic effects of ultraviolet radiation and oxygen. The structures of beta carotene, letein, zeaxanthin and astaxanthin are shown below. Astixanthin is a powerful free radical scavenger antioxidant increasingly recognized for its disease-fighting properties. It is used as a dietary supplement and also used in cosmetics because of its ability to protect against UV radiation.

Beta Carotene

Lutein

Zeaxanthin

Astaxanthin

Lutein, zeaxanthin and meso-xanthin which are naturally present in the macula of the human retina, filter out potentially phototoxic blue light and near-ultraviolet radiation from the macula (28). The protective effect is also in part due to the reactive oxygen species quenching ability of these carotenoids. Furthermore, lutein and zeaxanthin are more stable to decomposition by oxidants such as those arising from the reaction of light with oxygen than are other carotenoids such as beta-carotene. Zeaxanthin is the predominant pigment in the fovea, the region at the center of the macula. The quantity of zeaxanthin gradually decreases and the quantity of lutein increases in the region surrounding the fovea, and lutein is the predominant pigment at the outermost periphery of the macula. Zeaxanthin, which is fully conjugated (lutein is not), may offer somewhat better protection than lutein against phototoxic damage caused by blue and near-ultraviolet light radiation. These carotioids are orally absorbed and the macular density of these pigments correlates with serum concentration. Astaxanthin, a more potent antioxidant than other carotenoids has been used as a food supplement, has been shown to inhibit choroidal neovascularization (25). The occurrence of zeaxanthin, meso-zeaxanthin and lutein in the retina, but with different spatial distribution, suggests that a mixture with or without beta-carotene, might exert a more efficacious antioxidant activity over the entire macula than lutein by itself.

The ingredients of AREDS type supplements are delivered to the macula by transportation from the capillaries of the choroid. In AMD the choroidal blood flow is lower than normal and the transport of members of the antioxidant formula into the macula may not be maximal. Increasing choroidal blood flow by co-administration of fenoldopam may enhance transport of members of the antioxidant formula into the macula, especially in areas of poor blood flow susceptible to drusen formation. This could be accomplished by independent dosing with separate dosage forms, or preferably by incorporating fenoldopam and the antioxidant mixture into one dosage form. Since the beneficial effects of the antioxidant mixture and a D1/D5 agonist are due to different mechanisms, an additive or even a synergistic effect may be seen.

A dosage form can contain both fenoldopam and one or more members of the antioxidant-vitamin-mineral mixture. Such a dosage form could release all the components normally, or it could release one or more of the components over an extended period of time.

Aromatic or heteroaromatic fenoldopam esters for enhancing trans scleral topical absorption are shown in Structure I.

Structure I

Compounds useful as prodrugs include compounds of Structure I in which Ri, R₂, and R₃ may be the same or different and may be

wherein X and Y are independently S, O, N, NRs

-R8

A is H or ° , and when A is H, it may form a pharmaceutically acceptable salt of an acid such as hydrochloric, hydrobromic, methanesulfonic, alkyl sulfonic acid of 1 to 4 carbon atoms branched or unbranched, arylsulfonic, alkanoic acid of 2-6 carbons unbranched or branched, aryl or heteroaryl carboxylic acid;

R₅, R₆, R₇ are independently H, F, Cl, CF₃, Br, I, alkyl of 1 to 6 carbons branched or unbranched, or chains of 3 to 5 atoms including C, N, S, O, with or without double bonds, with or without attached R5, R^, R₇ groups, which may comprise two adjacent R₅, R^,or R₇ groups to form a closed ring; R₈ is an alkyl group of 1-10 carbon atoms which may be unbranched or branched, a heteroalkylgroup containing O, N, S, SO₂, or NR₄ which may be unbranched or branched, a heterocyclic group containing C, O, N, S, SO₂, or NR₄, an alkyloxycarbonyloxymethyleneoxy group in which the alkyl group has 1 to 6 carbons which may be branched or straight chain, and the methylene group may be unsubstituted or be substituted by 1 or 2 alkyl groups of 1-3 carbons and one or two of Ri (C=O)-, R₂ (C=O)-, R₃ (C=O)- may be replaced by H; and

R₄ is H, R₁, R₅, Ri(C=O), or R₅ (C=O). In particular embodiments, Ri, R₂, R₃ in the compounds of Structure I may represent a phenyl or naphthyl (1- or 2-) moiety, substituted with one or more of the R₅, R_f1, R7 groups.

A particular species which may be used in the practice of this invention is 6- Chloro-7,8-di-benzoyloxy-l-(p-benzoyloxyphenyl)-2,3,4,5-tetrahydro-lH-3- benzazepine hydrochloride.

A number of patent and non-patent publications are cited throughout the foregoing specification in order to describe the state-of-the-art to which this invention pertains. The entire disclosure of each of these publications is incorporated by reference herein. While certain embodiments of the present invention have been described and/or exemplified above, various other embodiments will be apparent to those skilled in the art from the foregoing specification. The present invention is, therefore, not limited to the particular embodiments described and/or exemplified, but is capable of considerable variation and modification without departure from the scope of the appended claims.

References

1. Gehrs KM, Anderson DH et al, Age-related macular degeneration-emerging pathogenic and therapeutic concepts, Annals of Medicine, 2006, 38, 459- 471.

2. ARVO 2002. Report of the 2002 meeting of the Association for Research in Vision and Ophthalmology.

3. Age -Related Eye Disease Study Research Group, A randomized, placebo- controlled, clinical trial of high dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001, 119, 1417-1436.

4. Macular Degeneration Foundation, Chapter 3. http:eyesight.org.

5. Huemer KH, Zawinka et al, Effects of dopamine on retinal and choroidal blood flow parameters in humans, Br J Ophthalmol, published online 23 Mar 2007. 6. Reitsamer HA, Zawinka, and Branka M, Dopaminergic vasodilation in the choroidal circulatin by D1/D5 Receptor Activation, Investigative Opthalmology and Visual Science, 2004, 45, 900-905.

7. Hegde SS, Lokhandwala MF, Renal dopamine and sodium excretion, Am J Hypertension, 1990, 3 (6 pt 2) 78S-81S,

8. Hegde SS, Ricci A et al, Evidence from functional and autoradiographic studies for the presence of tubular dopamine- 1 receptors and their involvement in the renal effects of fenoldopam, J Pharmacol Exp Ther. 1989, 251(3): 1237-45.

9. Clark KL, Hilditcch A et al, Effects of dopamine DAl -receptor blockade and angiotensin converting enzyme inhibition on the renal actions of fenoldopam in the anaesthetized dog, J Hypertens. 1991, 9 (12):1143-50.

10. Amenta F and Ricci A, Autoradiographic localization of dopamine DA-I receptors in the rat renal vasculature using [3H]-SCH 23390 as a ligand,

J Auton Pharmacol. 1990, 10 (6),373-83. 11. Roberts D, Summary of new research, Association of Research in Vision and Ophthalmology (ARVO), http://www.mdsupport.org/library/summarv2006/html.

12. Thoma K, Ziegler I, Simultaneous quantification of released succinic acid and a weakly basic drug compound in dissolution media.

Eur J Pharm Biopharm. 1998, 46 (2), 183-90. 13. U.S. Patent 6,238,693. Transdermal administration of fenoldolpam, May 29, 2001. Luther RR, McGuire D, Mathur V, Ellis DJ, Assignee: Elan Pharmaceuticals, Inc. 14. U.S. Patent 6,960,353. Formulations for the transdermal administration of fenoldopam, Nov 1, 2005. van Osdol WW, Crisologo NM, Yum, SI, Assignee: Alza Corporation.

15. U.S. Patent 6,699,497. Formulations for the transdermal administration of fenoldopam, Nov 1, 2005. van Osdol WW, Crisologo NM, Nieves M, Yum

SI, Assignee: Alza Corporation.

16. Brooks DP, DePalma PD, Identification of fenoldopam prodrugs with prolonged renal vasodilator activity, J Pharmacol Exp Ther. 1990, 254(3),1084-9.

17. Gaitanopoulos, D, Mico B, Weinstock J, Preparation of fenoldopam carbamates as antihypertensive agents, US Patent 4,861,771 (1989). 18. US Food and Drug Administration, Center for Drug Evaluation and

Research, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/

19. Carey RM, Stote RM et al, Selective Peripheral Dopamine Receptor Stimulation with Fenoldopam in Human Essential Hypertension, J Clin Invest. 1984, 74(6):2198-207.

20. Weinstock J, Hieble JP, and Wilson JW, The Chemistry and Pharmacology of 3 -Benzazepine Derivatives, Drugs of the Future, 1985, 10, 645-697. 21. Mogk LG, Geringer C, et al, The Impact of Dry vs. Wet Macular

Degeneration, ARVO 2008, Abstract, Program 4473, Poster D1064.

22. Doukas J, Mahesh S, Umeda N, Kachi S, Akiyama H, Yokoi K, Cao J, Chen Z, Dellamary L, Tarn B, Racanelli-Layton A, Hood J, Martin M, Noronha G, Soil R, Campochiaro PA., Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema, J Cell Physiol. 2008, 216(l):29-37.

23. Adv Drug Deliv Rev. 2005 Dec 13;57(14):2063-79, Myles ME, Neumann DM, Hill JM, Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis, Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis, Adv Drug Deliv Rev. 2005, 57(14), 2063-79.

24. Weinstock, J, 6-Halo-7,8-dihydroxy-l-(hydroxyphenyl)-2,3,4,5-tetrahydro- lH-3-benzazepines, US Patent 4,197,297 (1980).

25. Kanako Izumi-Nagai, Norihiro Nagai, Kazuhiro Ohgami, Shingo Satofuka, Yoko Ozawa, Kazuo Tsubota, Shigeaki Ohno, Yuichi Oike, and Susumu Ishida, Inhibition of Choroidal Neovascularization with an Antiinflammatory Carotenoid Astaxanthin, Investigative Ophthalmology and Visual Science. 2008, 49, 1679-1685.

26. Venkatesh GM, Development of controlled-release SK&F 82526-J buffer bead formulations with tartaric acid as the buffer, Pharm Dev Technol. 1998,

3(4), 477-85.

27. Physicians Desk Reference, 2003, 57, 412-414.

28. Bone RA, Landrum JT, Guerra LH, Ruiz CA, Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr 2003, 133, 992-998.

29. Carotenoids and Retinoids: Molecular Aspects and Health Issues. Editors Lester Packer, Ute Obermueller-Jevic, Klaus Kraemer, and Helmut Sies. AOCS Press, 2005. ISBN #1-893997-83-9

30. Carotenoids in Health and Disease. Editors Norman I. Krinsky, Susan T. Mayne, Helmut Sies. Marcel Dekker, Inc. New York, 2004. ISBN #0-8247- 5416-6. 31. Carotenoids - Handbook, G. Britton, S. Liaaen- Jensen and H. Pfander (eds).

Birkhauser Verlag, 2004.

32. Rattner A and Nathans J, Macular degeneration: recent advances and therapeutic opportunities. Nat Rev Neurosci. 2006, 7(11), 860-72.

Claims

WHAT IS CLAIMED IS:

1. A method for treating dry age-related macular degeneration, and preventing or delaying the onset of wet age-related macular degeneration, in a patient in need of said treatment, the method comprising administering to said patient a therapeutically effective amount of a dopamine agonist, said dopamine agonist having at least the following properties: highly selective as a DA 1/5 agonist with no significant D2 activity, no significant other catechol amine activity, does not cross the blood-brain barrier, and has the ability to increase choroidal blood flow over a therapeutically useful period of time with appropriate dosing.

2. A method for treating dry age-related macular degeneration, and preventing or delaying the onset of wet age-related macular degeneration (AMD), in a patient in need of said treatment, the method comprising administering to said patient a therapeutically effective amount of a dopamine agonist, said dopamine agonist having at least the following properties: highly selective as a DA 1/5 agonist with no significant D2 activity, no significant other catechol amine activity, and has the ability to increase choroidal blood flow over a therapeutically useful period of time with appropriate dosing and to access the ocular vasculature by topical administration.

3. A method for treating dry age-related macular degeneration, and preventing or delaying the onset of wet age-related macular degeneration (AMD) in a patient in need thereof, the method comprising administering to said patient a therapeutically effective amount of fenoldopam , a pharmaceutically acceptable salt thereof, a prodrug that yields fenoldopam, or a pharmaceutically acceptable salt of said prodrug.

4. The method of claim 3, wherein at least one salt selected from the group of fenoldopam mesylate, acid halides, sulfate, acetate, propionate, succinate, citrate, fumarate, benzoate is administered to said patient.

5. A method for treating, preventing or delaying the onset of dry age-related macular degeneration in a patient in need thereof, the method comprising administering to said patient a therapeutically effective amount of at least one fenoldopam prodrug selected from the group of fenoldopam carbamates, N- carbamates of fenoldopam or fenoldopam esters.

6. The method of claim 5, wherein a fenoldopam carbamate is administered which is 6-chloro-7,8-diethylcarbamoyl-l-(4'-ethylcarbamoylphenyl)-2, 3,4,5- tetrahydro-lH-3-benzazepine or a nontoxic pharmaceutically acceptable acid addition salts thereof.

7. The method of claim 5, wherein a N-carbamate of fenoldopam is administered which is an N-alkoxycarbamate.

8. The method of claim 5, wherein fenoldopam tri-esters is administered, which is the 7,8,4 - tris acetate, propionate, isobutyrate, valerate, pivaloate, and benzoate (or substituted benzoate) or a nontoxic pharmaceutically acceptable acid addition salts thereof.

9. The method of claims 3-8 wherein the R-enantiomer of fenoldopam is administered to said patient.

10. A method for enhancing the transport of at least one ophthalmic agent into the eye, said method comprising administering said ophthalmic agent in conjunction with a dopamine agonist, as claimed in claims 1 or 2, fenoldopam, a nontoxic pharmaceutically acceptable salt of fenoldopam, a fenoldopam prodrug or a nontoxic pharmaceutically acceptable salt of a fenoldopam prodrug.

1 1. A method of claims 1-10 wherein said dopamine agonist, fenoldopam, fenoldopam salt, fenoldopam prodrug, or fenoldopam prodrug salt, is administered in combination with Vitamin C (ascorbic acid), Vitamin E (alpha- tocopherol acetate), zinc as zinc oxide, copper as cupric oxide, and at least one of beta-carotene, lutein, astaxanthin, zeaxanthin and meso-xanthin.

12. The method of claims 1-11 wherein said dopamine agonist, fenoldopam, nontoxic pharmaceutically acceptable salt of fenoldopam, fenoldopam prodrug or nontoxic pharmaceutically acceptable salt of fenoldopam prodrug is administered in an oral dosage form.

13. The method of claim 12, wherein said oral dosage form is a sustained release formulation.

14. The method of claims 1-11 wherein said dopamine agonist, fenoldopam, nontoxic pharmaceutically acceptable salt of fenoldopam, fenoldopam prodrug or nontoxic pharmaceutically acceptable salt of fenoldopam prodrug is administered by a topical, trans-scleral, transdermal or nasal route of administration, or via a depot or pumped reservoir system.

15. The method of claim 14, wherein eye drops or an ointment is used to effect trans-scleral administration.

16. The use of said dopamine agonist, fenoldopam, nontoxic pharmaceutically acceptable salt of fenoldopam, fenoldopam prodrug or nontoxic pharmaceutically acceptable salt of fenoldopam prodrug as claimed in claims 1 - 15 in the manufacture of a medicant for the treatment of dry age-related macular degeneration.

17. The method of claim 9, wherein said therapeutically effective amount is an amount sufficient to provide a drug plasma level of fenoldopam of 0.25 to 20 ng/ml (0.5 to 10 ng/ml of R- fenoldopam), a preferred fenoldopam plasma level of 0.25 to 10 ng/ml (0.25 to 5 ng/ml of R fenoldopam) and a most preferred fenoldopam plasma drug level of 0.25 to 2.5 ng/ml (0.125 tol .25 ng/ml of R- fenoldopam) for the treatment of dry age related macular degeneration.

18. The method of claim 11, in which there is administered an amount of vitamin C sufficient to provide a daily dose of 300 to 600 mg, an amount of vitamin E sufficient to provide a daily dose of 200 to 500 IU, an amount of zinc oxide sufficient to provide a daily dose of 60 to 100 mg of zinc as zinc oxide, an amount of copper sufficient to provide a daily dose of 1.5 to 2.5 mg of copper as cupric oxide, an amount of beta-carotene sufficient to provide a daily dose of 0 to 20 mg, an amount of lutein sufficient to provide a daily dose of 0 to 10 mg, an amount of zeaxanthin sufficient to provide a daily dose of 0 to 10 mg, an amount of meso-xanthin sufficient to provide a daily dose of 0 to 20 mg, and an amount of astaxanthin is 0 to 10 mg.

19. The method of claim 18, wherein fenoldopam is administered in an extended release formulation and one or more of said other compounds are administered in an immediate release formulation.

20. A compound of the formula:

wherein R₁, R₂ and R₃ may be the same or different and may be

wherein X and Y are independently S, O, N, NRs

-R8

A is H or ° , and when A is H, it may form a pharmaceutically acceptable salt of an acid such as hydrochloric, hydrobromic, methanesulfonic, alkyl sulfonic acid of 1 to 4 carbon atoms branched or unbranched, arylsulfonic, alkanoic acid of 2-6 carbons unbranched or branched, aryl or heteroaryl carboxylic acid. R₅,R₆,R₇ are independently H, F, Cl, CF₃, Br, I, alkyl of 1 to 6 carbons branched or unbranched, or chains of 3 to 5 atoms including C, N, S, O, with or without double bonds, with or without attached R₅, R_O, R₇ groups, which may comprise two adjacent R₅, R^or R₇ groups to form a closed ring;

Rg is an alkyl group of 1-10 carbon atoms which may be unbranched or branched, a heteroalkylgroup containing O, N, S, SO₂, or NR4 which may be unbranched or branched, a heterocyclic group containing C, O, N, S, SO2, or NR4, an alkyloxycarbonyloxymethyleneoxy group in which the alkyl group has 1 to 6 carbons which may be branched or straight chain, and the methylene group may be unsubstituted or be substituted by 1 or 2 alkyl groups of 1-3 carbons and one or two of Ri (C=O)-, R₂ (C=O)-, R₃ (C=O)- may be replaced by H; and

R₄ is H, Ri, R₅, Ri(C=O), or R₅ (C=O).

21. The compound of compounds from Claim 20 in which Ri, R₂, R₃ represent a phenyl or naphthyl (1- or 2-) moiety, substituted with one or more of the R₅, RO, R₇ groups.

22. 6-Chloro-7,8-dibenzoyloxy-l-(p-benzoyloxyphenyl)-2,3,4,5-tetrahydro-lH-3- benzazepine hydrochloride.